Skip to Content
Merck
All Photos(3)

Documents

SML3953

Sigma-Aldrich

Istaroxime hydrochloride

≥98% (HPLC)

Synonym(s):

Androstane-3,6,17-trione, 3-[O-(2-aminoethyl)oxime], hydrochloride (1:1)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H32N2O3·HCl
CAS Number:
Molecular Weight:
396.95
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Positive inotropic agent that inhibits Na + /K + -ATPase and increases activity of Ca 2+ -ATPase at the sarcoplasmic reticulum.



Istaroxime is a positive inotropic agent that inhibits Na + /K + -ATPase and increases activity of Ca 2+ -ATPase at the sarcoplasmic reticulum. It improves cardiac performance in the failing heart. Istaroxime ameliorates calcium dysregulation Zebrafish PLN R14del arrhythmogenic cardiomyopathy model.

Caution

Hygroscopic

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

STOT RE 2

Target Organs

Gastro-intestinal system,Heart

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy
Cardiovascular Research, 118(4), 1020-1032 (2022)
Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure
The American Journal of Cardiology, 99(2A), 24A-32A (2007)
S M Kamel et al.
Nature communications, 12(1), 7151-7151 (2021-12-11)
The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service